Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty‐year experience (1975 to 1996)

Chim, Chor Sang; Liang, Raymond; Kwong, Yok–Lam; Todd, D.; Chan, T. K.

doi:10.1111/j.1445-5994.1999.tb01622.x

Cited by 3 publications

(2 citation statements)

References 33 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk factors for poor OS were age more than 50 years, ECOG > 2, unfavorable cytogenetic profile, receiving induction regimen less than "7+3" regimen (including "5+2" regimen [Cytarabine 5 days plus Idarubicin 2 days] or low or Intermediate dose of cytarabine or best supportive care), leukostasis and not achieve CR after 1 induction cycle. The results were in line with previous studies [3,6,8,[19][20][21][30][31][32][38][39][40][41]. Death rate of APL patients was obviously high in 6 months after diagnosis during induction and consolidation.…”

Section: Discussionsupporting

confidence: 91%

“…The favorable outcomes presence in terms of higher CR rate, lower relapsed rate, and better OS. CR rate in both subtypes were similar to existing studies [8,[30][31][32][33][34][35][36][37]. Risk factors for poor OS were age more than 50 years, ECOG > 2, unfavorable cytogenetic profile, receiving induction regimen less than "7+3" regimen (including "5+2" regimen [Cytarabine 5 days plus Idarubicin 2 days] or low or Intermediate dose of cytarabine or best supportive care), leukostasis and not achieve CR after 1 induction cycle.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG)

Wanitpongpun

Utchariyaprasit

Owattanapanich

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 84%

Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG)

Wanitpongpun

Utchariyaprasit

Owattanapanich

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

show abstract

Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias

2004

View full text Add to dashboard Cite

SOCS1 and SHP1 are negative regulators of the Jak/STAT signalling pathway that is implicated in leukaemogenesis. We studied if aberrant methylation of SOCS1 and SHP1 might be involved in the pathogenesis and prognostication of acute leukaemias by methylation-specific polymerase chain reaction (MSP). At diagnosis, methylation of SHP1 occurred more frequently in acute myeloid leukaemia (AML) (n=26, 52%) than acute lymphoblastic leukaemia (ALL) (n=6, 24%) (p=0.02). Methylation of SOCS1 was absent in both AML and ALL patients. SHP1 methylation was not associated with specific clinicopathologic features and had no prognostic impact on AML patients. Frequent methylation of SHP1, but not SOCS1, may be important in the pathogenesis, but not prognosis, of acute leukaemias.

show abstract

Adverse prognostic impact ofCDKN2Bhyper-methylationin acute promyelocytic leukemia

Chim

Kwong

2006

Leukemia & Lymphoma

View full text Add to dashboard Cite

The use of all-trans retinoic acid (ATRA) has markedly improved the survival of patients with acute promyelocytic leukemia (APL), making it potentially curable. However, the identification of prognostic markers predictive of durable remission remains an important aspect in risk-adjusted treatment algorithms. High presentation leucocyte count has been found to correlate with inferior disease-free-survival (DFS). However, recent studies have also shown aberrant promoter methylation of the CDKN2B (alias p15) gene to be a negative prognostic factor. Promoter methylation results in the formation of a repressor complex, leading to chromatin compaction and suppression of gene expression and is, therefore, an alternative mechanism of gene inactivation. CDKN2B, a cyclin-dependent kinase inhibitor, is a tumor suppressor gene inhibiting cell cycle progression. The CpG island inside the CDKN2B promoter is hyper-methylated in approximately 50 - 60% of APL patients. CDKN2B methylation correlates negatively with DFS. As methylation-induced inactivation of CDKN2B pre-disposes to unchecked cellular proliferation, CDKN2B hyper-methylation is also associated with high presentation leucocyte count. Multivariate analysis in several studies, however, has shown that the negative prognostic impact of CDKN2B methylation is independent of its association with high leucocyte counts. Therefore, CDKN2B methylation is a potential prognostic factor that may be incorporated into a risk-stratified therapeutic strategy, which aims at achieving a cure with optimal amounts of treatment.

show abstract

Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty‐year experience (1975 to 1996)

Abstract: Our experience confirmed the efficacy of standard-dose Ara-C/daunorubicin and the prognostic value of age and FAB subtype. Median and projected DFS were similar to western studies.

Cited by 3 publications

References 33 publications

Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG)

Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG)

Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias

Adverse prognostic impact ofCDKN2Bhyper-methylationin acute promyelocytic leukemia

Contact Info

Product

Resources

About